# A Study of the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of JNJ-47910382 at Different Doses and Dose Regimens in Asian Genotype-1, Chronic, HCV-Infected Patients

> **NCT01586325** · PHASE1 · TERMINATED · sponsor: **Janssen R&D Ireland** · enrollment: 8 (actual)

## Conditions studied

- Chronic Hepatitis C Infection

## Interventions

- **DRUG:** JNJ-47910382 30 mg
- **DRUG:** JNJ-47910382 90 mg
- **DRUG:** JNJ-47910382 200 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01586325
- **Lead sponsor:** Janssen R&D Ireland
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-05-25
- **Primary completion:** 2014-04-21
- **Final completion:** 2014-04-21
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** Because of many competing trials using the same mechanism of action, but being further advanced in development
- **Last updated:** 2019-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01586325

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01586325, "A Study of the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of JNJ-47910382 at Different Doses and Dose Regimens in Asian Genotype-1, Chronic, HCV-Infected Patients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01586325. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*